This raises questions about the relevance of PD-L1 expression as a biomarker for patients with advanced METex14 NSCLC, as well as the safety and efficacy of ICIs in this population; notably the balance between potential efficacy and toxicity associated with receiving TKIs, in particular crizotinib, following ICI therapy [95,98]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.